Intubation Induction Agents

This page does not choose an agent. It shows what each source says, with the kind of evidence beside it.

What the sources say, by condition

Patient
Condition

Pick a condition. Neonate, nonemergency shows the newborn premedication statement as well.

No randomized trial of an induction agent in children with heart disease was found: the condition panels rest on cohorts, small studies, reviews and a textbook. kind of evidence abstract = read in the abstract only.

Drug effects

Check every dose against your formulary. Doses are in the closed box under each drug, each with its source and the age it applies to.

Arrows only where a source states the direction. n/s: not stated in the sources read, not the same as no change.
DrugSVRPVRContractilityHeart rateWatch for
Ketamine↑ (textbook); no significant change in small studiesNo significant change; minimal (AHA/ATS 2015)Direct depressant; sympathetic release (textbook)↑ (textbook, label)Contraindicated where a blood pressure rise is a serious hazard (label)
EtomidateNo significant change (Sarkar 2005, Dhawan 2010)No significant change (Sarkar 2005)n/s; cardiac output little changed (label)No significant change (Dhawan 2010)Adrenal suppression after one dose; under 10 y not recommended (label)
Propofol↓ (textbook)Minimal (AHA/ATS 2015)↓ (textbook)Bradycardia, asystole reported (label)Hypotension; induction under 3 y not recommended (label)
Midazolamn/sn/sn/sWith fentanyl, lower output through lower rate (textbook)Hypotension; no analgesia; not alone in neonates (CPS 2026)
FentanylSmall ↓ (Hickey 1985, fentanyl)No significant change; blunts the rise with suctioningCardiac index unchanged (Hickey 1985, fentanyl)Bradycardia (textbook, label)Chest wall rigidity: give slowly (CPS 2026, label)
Dexmedetomidine adjunct↑ with loading dose or bolusNo significant changeCardiac index unchanged (Friesen 2013)↓; sinus and AV node depressed (Hammer 2008)Bradycardia, hypertension, hypotension (label)
Rocuroniumn/sn/sn/sTransient rise after intubation without atropine (label)Not recommended for pediatric rapid sequence intubation (label)
Succinylcholinen/sn/sn/sBradycardia, rarely asystole; worse in children (label)Boxed warning: hyperkalemic arrest with undiagnosed myopathy (label)
Atropinen/sn/sn/s↑ (Jones 2013)Neonates: associated with more desaturation, lower first-attempt success (Sawyer 2026, registry)
Ketamine: uses, side effects, doses
Class
NMDA receptor antagonist (Ungerleider 2019, Table 21.1)
Effects
Raises SVR and lessens right-to-left shunting; sympathetic activation and catecholamine release, but a direct myocardial depressant (Ungerleider 2019) textbook. Heart rate up, MAP stable; loses its cardiovascular support when catecholamines are depleted (Table 21.1) textbook. Transient rises in blood pressure, heart rate and cardiac index are frequent; falls, arrhythmias and cardiac decompensation also occur (label). Ventilated infants: no significant change in CI, PVRI or SVRI (Hickey 1985, ketamine) small studyabstract; 7 studies, 139 children: PVR, SVR, PA pressure and heart rate not significantly changed (Loomba 2018) meta-analysisabstract
Side effects
Contraindicated where a significant blood pressure rise would be a serious hazard; emergence reactions (about 12%); respiratory depression if given fast or in overdose; does not suppress pharyngeal and laryngeal reflexes; salivation, so an antisialagogue first (FDA label)
Doses
  • Label Induction 1–4.5 mg/kg IV over 60 seconds, average 2 mg/kg; IM 6.5–13 mg/kg. The label gives no age for these doses and says safety and effectiveness under 16 years are not established (FDA label, Ketalar)
  • Child Study dose 2 mg/kg IV in children with PH, over 5 minutes (Williams 2007) or 2 minutes (Friesen 2016)
  • Neonate No dose: too little experience to recommend (CPS 2026)
Etomidate: uses, side effects, doses
Class
Imidazole derivative (Ungerleider 2019)
Effects
No significant change in RA, aortic or PA pressure, Qp:Qs, SVR or PVR after 0.3 mg/kg in 12 children (Sarkar 2005) small studyabstract; no significant change in heart rate, SVRI or Qp:Qs in 30 children with shunts, nor PVRI in the left-to-right group (Dhawan 2010) small studyabstract. Up to 0.6 mg/kg in severe cardiovascular disease: little or no effect on cardiac output or pulmonary circulation (label)
Side effects
Lower cortisol for about 6–8 h after 0.3 mg/kg, not reversed by ACTH; not for prolonged infusion; venous pain on injection (about 20%); transient muscle movements including myoclonus (FDA label). One dose lowered adrenal function for at least 24 h in children with meningococcal sepsis (den Brinker 2008) cohort
Used for
Septic shock: see that panel. Adult trial against ketamine: see Septic shock
Doses
  • Over 10 y 0.2–0.6 mg/kg IV, usual 0.3 mg/kg over 30–60 seconds; under 10 years not recommended, too few data (FDA label, Amidate)
  • Child Study dose 0.3 mg/kg (Sarkar 2005, Dhawan 2010)
Propofol: uses, side effects, doses
Class
Phenol; potentiates GABAA activity (Ungerleider 2019, Table 21.1)
Effects
SVR, MAP and contractility down (Table 21.1) textbook; minimal effect on PA pressure and PVRI (AHA/ATS 2015) guideline
Side effects
Hypotension at induction; bradycardia, asystole and cardiac arrest reported, children especially with fentanyl; contraindicated with a history of anaphylaxis to egg or soy (FDA label). Preterm infants 29–32 weeks: 1 mg/kg dropped MAP from 38 to 24 mmHg and the study was stopped (Welzing 2010) small studyabstract. Against morphine, atropine and suxamethonium in 63 infants: faster intubation, blood pressure and heart rate no different (Ghanta 2007) RCTabstract
Doses
  • 3–16 y ASA I–II: 2.5–3.5 mg/kg; lower in ASA III–IV; induction under 3 years not recommended (FDA label, Diprivan)
  • Neonate No recommended dose: no optimal dose found in a dose-finding trial (de Kort 2020); alone, not recommended (CPS 2026)
Midazolam: uses, side effects, doses
Class
Benzodiazepine (Ungerleider 2019, Table 21.1)
Effects
Cardiovascular effects minimal (Table 21.1); with fentanyl, lower cardiac output from a lower heart rate (Ungerleider 2019) textbook
Side effects
No analgesia; lowers blood pressure; long, variable half-life can delay spontaneous breathing; more adverse events in more preterm infants (CPS 2026)
Doses
  • No pediatric induction dose on the FDA label (Midazolam Injection); not alone in neonates (CPS 2026)
Fentanyl, remifentanil, morphine: uses, side effects, doses
Class
Opioid (Ungerleider 2019, Table 21.1)
Effects
25 mcg/kg in 12 infants after repair: heart rate, CI, PA pressure and PVRI not significantly changed; small fall in MAP and SVRI (Hickey 1985, fentanyl) small studyabstract. Low impact on hemodynamics; titrated fentanyl suits limited cardiac reserve (Ungerleider 2019) textbook
Side effects
Muscle rigidity, including respiratory muscles, managed with a neuromuscular blocker; severe bradycardia and hypotension (FDA label). Give slowly over 2–5 minutes, ready to ventilate (CPS 2026). Higher doses may decompensate catecholamine-dependent patients (Ungerleider 2019)
Others
Remifentanil: fast, cleared quickly, less dependent on liver and kidney; same rigidity risk. Morphine: ineffective for intubation, slow onset (CPS 2026)
Doses
  • Neonate 2 mcg/kg IV, slow push over 2–5 minutes (intubation, INSURE); 1 mcg/kg (LISA, MIST); no IV access: intranasal 1–2 mcg/kg (CPS 2026, Table 1)
  • Neonate Remifentanil 1 mcg/kg may be considered as an alternative opiate (CPS 2026)
  • 2–12 y Reduced dose, as low as 2–3 mcg/kg, for induction and maintenance; under 2 years safety and efficacy not established (FDA label, Fentanyl Citrate Injection)
Dexmedetomidine: uses, side effects, doses
Class
α2-adrenergic agonist (Ungerleider 2019, Table 21.1). An adjunct, not an induction agent, in the sources read
Effects
Heart rate down, blood pressure up; sinus and AV nodal function depressed, 12 children at EP study (Hammer 2008) small studyabstract. Rapid bolus after heart transplant: blood pressure, PA pressures and SVR up at 1 minute, near baseline by 5; PVR and cardiac output unchanged (Jooste 2010) small studyabstract
Side effects
Bradycardia and hypotension from reduced sympathetic outflow; not ideal for EP studies (Ungerleider 2019)
Doses
  • No dose for intubation: the FDA pediatric indication is sedation of non-intubated patients, 1 month to under 18 years, for non-invasive procedures (FDA label, Precedex)
  • Child Study doses: 0.5, 0.75 or 1 mcg/kg over 10 minutes (Friesen 2013); 1 mcg/kg over 10 minutes (Hammer 2008); 0.25 or 0.5 mcg/kg over 5 seconds in anesthetized heart-transplant patients at cath; blood pressure and SVR rose at 1 minute (Jooste 2010)
Rocuronium: uses, side effects, doses
Class
Nondepolarizing muscle relaxant (CPS 2026)
Effects
Under halothane without atropine, about 80% of children had a transient heart rate rise of 30% or more after intubation (FDA label)
Side effects
Onset 1–3 minutes; in neonates a longer, variable action, up to an hour (CPS 2026). Not recommended for rapid sequence intubation in children (FDA label)
Doses
  • Pediatric Initial intubating dose 0.6 mg/kg; 0.45 mg/kg may be used; studied from neonates to 17 years (FDA label, Rocuronium Bromide Injection)
Succinylcholine: uses, side effects, doses
Class
Depolarizing muscle relaxant; onset about 1 minute, lasts about 10 (CPS 2026)
Side effects
Boxed warning: hyperkalemic rhabdomyolysis with arrhythmia, arrest and death in apparently healthy children with undiagnosed myopathy, most often Duchenne; in children, keep it for emergency intubation or an airway that must be secured at once. Contraindicated with skeletal muscle myopathy, malignant hyperthermia susceptibility, and after the acute phase of major burns, multiple trauma, extensive denervation or upper motor neuron injury. IV bolus can cause profound bradycardia, rarely asystole, more in children and after a second dose; atropine first may reduce it (FDA label, Quelicin)
Doses
  • Neonate 2 mg/kg IV push (CPS 2026, Table 1)
  • Pediatric For emergency intubation or an airway that must be secured at once: infants and small children 2 mg/kg IV; older children and adolescents 1 mg/kg IV (FDA label, Quelicin)
Atropine: uses, side effects, doses
Class
Anticholinergic, vagolytic (CPS 2026)
Used for
Emergency intubation of infants and children: may be reasonable as premedication to prevent bradycardia (COR 2b, C-LD) (PALS 2025) guideline. Atropine at induction went with lower ICU mortality in children over 28 days and under 8 years (adjusted OR 0.22, 0.06–0.85), not in neonates; heart rate about 44–46 bpm higher (Jones 2013, 264 intubations) cohort. Glycopyrrolate also prevents bradycardia (CPS 2026)
Doses
  • Infant, child 0.02 mg/kg with no minimum dose may be considered (COR 2b, C-LD) (PALS 2025)
  • Neonate 0.01–0.02 mg/kg IV push (CPS 2026, Table 1)

Neonates, infants and children with heart disease. Adult data labelled Adult.

Key points

Sources and how this page was checked

Full text read

Abstract only

FDA labels (DailyMed)

How it was checked